

# Molecular Diagnosis of Human Cutaneous Leishmaniasis and Identification of the Causative *Leishmania* Species in Iran: A Narrative Review

Seyed Ebrahim Eskandari<sup>1\*</sup>, Mojtaba Memariani<sup>2,3</sup>,  
Hamed Memariani<sup>4</sup>, Mehdi Mohebali<sup>5,6</sup>, Ali Khamesipour<sup>1</sup>

<sup>1</sup>Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran; <sup>2</sup>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; <sup>3</sup>Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran; <sup>4</sup>Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran; <sup>5</sup>Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; <sup>6</sup>Centers for Research of Endemic Parasites of Iran, Tehran University of Medical Sciences, Tehran, Iran

## OPEN ACCESS

Received: June 16, 2024

Accepted: June 29, 2024

Published online: June 30, 2024

**Citation:**

Eskandari SE, Memariani M, Memariani H, Mohebali M, Khamesipour A. Molecular Diagnosis of Human Cutaneous Leishmaniasis and Identification of the Causative *Leishmania* Species in Iran: A Narrative Review. *Iranian biomedical journal* 2024; 28(4): 148-155.

## ABSTRACT

Cutaneous leishmaniasis is a common form of leishmaniasis in underdeveloped countries. Although CL tends to be self-limiting, it can cause significant scars and may progress to more severe manifestations. Additionally, *Leishmania* species vary in susceptibility to the available treatments. The selection of treatment and clinical outcome of CL depend on the accurate determination of the *Leishmania* species. This mini-review aims to provide an overview of the molecular diagnosis techniques such as PCR-based assays, NASBA, and LAMP utilized in the identification of *Leishmania* species in Iran. DOI: 10.61186/ibj.4239

**Keywords:** Humans, Iran, Leishmaniasis, Molecular diagnostic techniques

**Corresponding Author:** Seyed Ebrahim Eskandari

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran; Tel.: (+98-21) 88960880; E-mail: crtssl\_eskandari@yahoo.com

## INTRODUCTION

Leishmaniasis generally manifests in four clinical forms: CL, DCL, MCL, and VL. Around 350 million people are estimated to be at the risk of leishmaniasis in nearly 100 countries. Annually, the incidence of VL ranges from 200,000 to 400,000 cases, while CL affects 700,000 to 1.2 million individuals, leading to an estimated 20,000 to 40,000 deaths<sup>[1]</sup>.

Identification of the particular species of *Leishmania* is necessary for accurate diagnosis and treatment of CL, as well as for successful patient management. CL is diagnosed based on clinical presentation, supported by epidemiological data, and laboratory testing<sup>[2]</sup>.

Furthermore, immune-compromised patients exhibit atypical manifestations with varying levels of metastatic dissemination of the pathogen, indicating that host immune status contributes to clinical outcomes<sup>[3]</sup>. Patients with localized CL also produce low levels of antibodies against the disease. However, immunocompromised patients, including those who are co-infected with the human immunodeficiency virus or are under chemotherapy, produce little or no antibodies, which results in negative serological tests<sup>[4,5]</sup>. Because of this, the patients may benefit from the enhanced sensitivity of molecular methods compared to serology tests<sup>[2,4,5]</sup>. Identification and differentiation of *Leishmania* species in various regions of the world have

### List of Abbreviations:

**AAP3:** amino acid permease 3; **AFLP:** amplified fragment length polymorphism; **AI:** artificial intelligence; **CI:** confidence interval; **CL:** cutaneous leishmaniasis; **COII:** cytochrome oxidase II; **cpb:** cysteine proteinase b; **DCL:** diffuse cutaneous leishmaniasis; **DIG:** digoxigenin; **DIG-dUTP:** digoxigenin-11-dUTP; **dNTP:** deoxynucleotide triphosphate; **ELISA:** enzyme-linked immunosorbent assay; **gp63:** glycoprotein 63; **ITS:** internal transcribed spacer; **kDNA:** kinetoplast DNA; **LAMP:** loop-mediated isothermal amplification; **MCL:** mucocutaneous leishmaniasis; **NASBA:** nucleic acid sequence-based amplification; **OC:** oligochromatography; **PCR:** polymerase chain reaction; **QT-NASBA:** quantitative nucleic acid sequence-based amplification; **RFLP:** restriction fragment length polymorphism; **rRNA:** ribosomal RNA; **RT-PCR:** reverse transcription PCR; **SAG:** sodium antimony gluconate; **SL RNA:** spliced leader RNA; **ssDNA:** single-stranded DNA; **TD-LAMP:** tape-disc LAMP; **VL:** visceral leishmaniasis

revealed new parasite-related disease manifestations. For instance, there is evidence that *L. donovani*, which is commonly associated with VL, may also present as CL disease. Moreover, the clinical overlap between VL and CL presentations has previously been described for *L. infantum/L. chagasi*<sup>[3]</sup>.

There are several diagnostic methods available for CL, including microscopy, histopathology, culturing, and molecular methods, all with varying levels of accuracy<sup>[6]</sup>. Indeed, the infrastructure and resources of the facility rather than diagnostic accuracy, determine the type of diagnostic test. However, diagnosis is still contingent upon direct parasitological methods<sup>[3]</sup>. The present review aims to cover important molecular diagnostic techniques with particular attention to Iranian studies. Finally, we touch on the potential of AI as an emerging tool that could aid in diagnosing CL.

## PCR-based methods

### Conventional PCR and PCR-RFLP

In epidemiological studies, PCR is often used along with other methodologies, such as RFLP analysis and gene sequencing to confirm different *Leishmania* species<sup>[6,7]</sup>. These techniques are of value in monitoring the progression of the disease, assessing the efficacy of antileishmanial treatment, discerning species-level differences, and identifying drug resistance<sup>[8]</sup>. Various target sequences, such as kDNA, small subunit rRNA, ITS of the ribosomal DNA, the mini-exon gene or the SL RNA gene, the tubulin gene, *gp63* gene, and repetitive genomic sequences, have been well described<sup>[9,10]</sup>. A high abundance of minicircles in the pathogen makes kDNA an attractive PCR target<sup>[10]</sup>. According to one study, the PCR assay based on kDNA, exhibited a high sensitivity (93.6%) in the diagnosis and identification of CL caused by *L. major*, *L. tropica*, and *L. infantum* in Shiraz City. This sensitivity was significantly higher than that of direct microscopy (76.7%) and culture methods (50.9%)<sup>[11]</sup>. Another study demonstrated that ITS-PCR had a higher level of sensitivity (98.8%) compared to microscopy (79.3%) and culturing assay (86.2%) for detecting *L. tropica* and *L. major* in Mashhad City<sup>[12]</sup>. ITS-PCR, followed by RFLP, was also successfully used to detect *L. major* in CL patients from Ilam Province, Iran<sup>[13]</sup>. Teimouri et al. utilized the same method to detect *L. tropica* and *L. major* in CL patients across different areas of Iran. Based on their results, *L. tropica* isolates exhibited a higher level of heterogeneity compared to *L. major* and *L. infantum* isolates<sup>[14]</sup>. By employing kDNA PCR-RFLP, Ghatee et al. observed a high diversity among *L. tropica* strains isolated from CL cases in Kerman and Shiraz cities<sup>[15]</sup>. Darudi et al. recommended kDNA PCR as an appropriate diagnostic tool for CL in endemic

areas and suggested ITS-PCR RFLP for the rapid characterization of *Leishmania* species<sup>[16]</sup>. A simple smear sample is sufficient to attain reliable results for PCR. The sensitivity of PCR in smear samples is 95% (95% CI: 90%-98%), while its specificity is 91% (95% CI: 70%-98%). However, its sensitivity and specificity are lower for aspirates, skin biopsies, and swab samples<sup>[17]</sup>.

### Nested and semi-nested PCR

Nested PCR minimizes non-specific amplification of DNA template. When a gene is present in low abundance, nested PCR could be a suitable technique for its amplification. The nested PCR technique allows to achieve results that are largely devoid of impurities due to primer dimers, alternative primer targets, and hairpins<sup>[18]</sup>. In a study by Feiz Haddad et al., the specificity and sensitivity of the nested PCR for detecting kDNA in CL patients were 92% and 100%, respectively<sup>[19]</sup>. Also, similar results were observed by Shirian et al. in patients with localized CL<sup>[20]</sup>. Similarly, Khosravi et al. detected *L. major* and *L. tropica* among CL patients in Kerman province, Iran<sup>[21]</sup>. The differentiation between *L. tropica* and *L. major* in the suspected cases of CL was also achieved using nested PCR in a study conducted in Ahvaz City, Iran<sup>[22]</sup>. Maraghi and co-workers successfully utilized nested PCR to differentiate *L. tropica* and *L. major* in lesions of patients with CL<sup>[23]</sup>. Several investigators also used semi-nested PCR to detect different *Leishmania* species in sandflies<sup>[24-26]</sup> and lesions of patients with CL<sup>[27,28]</sup> based on the primers targeting kDNA or ITS regions. For instance, in a study performed by Badirzadeh et al., the application of semi-nested PCR based on kDNA was effective in identifying *L. infantum* and *L. major* in Iranian patients with CL<sup>[29]</sup>. To reduce the risk of carryover in nested PCR, it is essential to implement physical separation of equipment and designated areas during various stages of the process<sup>[7]</sup>.

### Multiplex PCR

This method enables various DNA targets to be amplified concurrently, allowing multiple PCR reactions to be run at the same time. By using numerous primers in one PCR mixture, amplicons of specific DNA targets with varying sizes can be generated<sup>[7,9]</sup>. For leishmaniasis diagnosis, various markers, such as kDNA and SL RNA, have been employed<sup>[30-33]</sup>. In this context, Nateghi Rostami et al. designed a kDNA-based multiplex PCR for the simultaneous detection of *L. major*, *L. tropica*, and *L. infantum* in CL patients. They showed 100% sensitivity and 100 the isolates from lesion scrapings, exudates, and biopsy samples<sup>[34]</sup>. The effectiveness of multiplex PCR to detect *L. major* and *L.*

*tropica* in CL patients, was also demonstrated in another study performed in Tehran, Iran<sup>[35]</sup>.

### Real-time PCR

The application of real-time PCR provides benefits in diagnosing, monitoring clinical treatments, following up of patients, drug development, and drug efficacy evaluation<sup>[8,10,36]</sup>. Researchers have designed various real-time PCR protocols targeting *kDNA*, *tryparedoxin peroxidase* gene, and *ITS1*<sup>[8]</sup>. A number of internal controls, such as *GAPDH*,  $\beta$ -*microglobulin*,  $\beta$ -*actin*, and *18S rRNA* genes, have been used to determine optimal nucleic acid extraction and sample quality<sup>[9]</sup>. In Iran, the implementation of real-time PCR has proven to be successful in detecting various *Leishmania* species in CL patients. In a study conducted in the southwest of Iran, real-time PCR targeting *kDNA* on Giemsa-stained smears of the cutaneous lesions, which were collected from CL patients, was found to have a sensitivity of 98%<sup>[37]</sup>. In a separate work, the detection of *L. major* and *L. tropica* in CL patients was performed using real-time PCR targeting the *tryparedoxine peroxidase* gene. The sensitivity and specificity of this method were found to be 98.7% and 59.8%, respectively<sup>[38]</sup>. Real-time PCR based on ITS was also used to detect *L. tropica* in paraffin-embedded tissue samples and monitor the parasite load during treatment and following up in a study from Kerman, Iran<sup>[39]</sup>. Recently, Fotouhi-Ardakani et al. have devised a novel TaqMan real-time PCR technique, targeting two gene regions, AAP3 and COII, to identify *L. major* and *L. tropica* in CL samples collected from various regions of Iran. They achieved an outstanding sensitivity of 98.1% and a specificity of 100% for the method mentioned above in their study<sup>[40]</sup>. Overall, real-time PCR appears to be a promising technique, but its application is restricted by the high expenses and also the necessity for an expert to interpret the results.

### PCR-ELISA

In PCR-ELISA, PCR products are detected and quantified directly following the immobilization of biotinylated DNA on a microtiter plate using an immunological technique (ELISA)<sup>[41-43]</sup>. The method was successfully used for the diagnosis of CL using lesion scrapings, biopsies, and exudates<sup>[41-43]</sup>. In many studies, *kDNA* was employed as a target for PCR-ELISA<sup>[41,44]</sup>. In Iran, few studies applied PCR-ELISA for detecting *Leishmania* among patients. In a study conducted by Samimi et al., PCR-ELISA was utilized to detect *L. major* in patients diagnosed with CL in Golestan Province, Iran<sup>[42]</sup>. In another research work, the detection of *L. infantum* in blood samples of healthy individuals who reside in endemic regions was

conducted using PCR-ELISA targeting *kDNA*. The study indicated that the *kDNA*-based PCR-ELISA test cannot be considered a reliable method for diagnosing active VL in endemic areas, primarily due to the high prevalence of positive samples<sup>[44]</sup>.

### AFLP

AFLP is a multiplex PCR-based method that enables the observation of fragments produced by restriction endonucleases locating at random sites across the genome. This method allows researchers to gain a complete understanding of the genetic variations present in an organism's genome<sup>[45]</sup>. A comparative analysis of *L. donovani*, *L. major*, and *L. tropica* was performed using AFLP to search for markers that can differentiate visceral from cutaneous manifestations<sup>[46]</sup>. As for Iran, there are limited data on the use of the AFLP method for studying genetic variations in *Leishmania*. In one study, authors attempted to develop a cDNA-AFLP method confirmed by the real-time PCR, for identifying target genes associated with antimony resistance in clinical isolates of *L. tropica*<sup>[47]</sup>. A similar approach was also utilized for the identification of Glucantime® resistance markers in *L. infantum*<sup>[48]</sup>.

### NASBA

NASBA is a transcription-based amplification and isothermal complex method for determining RNA targets. By detecting RNA, NASBA is able to determine the viability of parasites<sup>[7]</sup>. By targeting RNA, a significantly higher number of template molecules will be available, leading to the enhanced sensitivity of the assay and a reduced sample volume. QT-NASBA could detect the levels of parasites 100-fold lower than those detected by conventional PCR<sup>[49]</sup>. The lower detection limit of QT-NASBA (based on *18S rRNA*) was two parasites per skin biopsy sample or  $10^2$  parasites/mL (corresponds to 0.1 parasites per  $\mu\text{L}$ ) of blood sample<sup>[49,50]</sup>. In Iran, limited efforts have been made to develop NASBA to detect *Leishmania*. Niazi et al. showed a sensitivity of 81% and a specificity of 100% for the NASBA method in detecting *L. major* in wound samples, while the sensitivity and specificity of RT-PCR were 51% and 100%, respectively<sup>[51]</sup>. One study also attempted to standardize *18S rRNA*-based NASBA for the detection of *L. major*<sup>[52]</sup>. Similarly, another study developed a colorimetric assay based on NASBA-GNR (*18S rRNA*-based NASBA assay combined with gold nanorods) for identifying *L. major* in skin biopsy samples. The results confirmed 100% sensitivity for NASBA-GNR assays compared to RT-PCR and also the specificity of the colorimetric assay was 80% in comparison with RT-PCR<sup>[53]</sup>.

## LAMP

The isothermal nature of the LAMP reaction obviates the requirement for a thermal cycler<sup>[9,54]</sup>. LAMP uses a strand-displacing DNA polymerase and often comprises four to six primers recognizing six to eight distinct regions of target DNA. The presence of amplified targets by LAMP can visually be identified as either a white precipitate or a solution with a yellow-green color upon the introduction of SYBR green dye. This combination of features renders the technique suitable for being used under field conditions<sup>[7]</sup>. Different targets such as kDNA, 18S rRNA gene, *cpb* gene, *ITS1* DNA sequences, *k26* or *hydrophilic surface protein B* gene, and *histone H3* gene were detected by LAMP assay<sup>[55]</sup>. LAMP can detect as low as 0.01 parasites/mL, whereas reverse transcription LAMP has a detection limit of 10–100 parasites/mL based on serial dilutions of extracted *Leishmania* DNA<sup>[54]</sup>. In one study, the LAMP assay based on 18S rRNA gene, was able to accurately detect *Leishmania* species in patients with CL in Khuzestan Province, Iran. The LAMP assay achieved a sensitivity of 98% and a specificity of 100%, whereas kDNA-based nested PCR yielded 100% sensitivity and specificity<sup>[56]</sup>. By contrast, another study showed that both real-time PCR and LAMP methods had 100% sensitivity and specificity in detecting *Leishmania* species in stained smears of cutaneous lesions<sup>[57]</sup>. Recently, Taslimi et al. successfully utilized TD-LAMP for diagnosing CL. Their findings revealed a sensitivity of 97% and a specificity of 100% in detecting *L. tropica* infection. The detection limit of the TD-LAMP assay was 1 fg<sup>[58]</sup>. Although the LAMP assay offers considerable ease and simplicity, there is a significant risk of cross-contamination.

## AI in CL diagnosis

AI can enable us to identify specific morphological features and patterns with exceptional accuracy. By integrating AI with telemedicine platforms, there has been an improvement in efficient patient management, follow-up, and tailored treatment plans, marking a new era in medical care. Recently, a new AI-driven system has been developed in Iran to identify *Leishmania* parasites in microscopic images. Notably, the system achieved a specificity of 52%, a sensitivity of 71%, and an accuracy of 70% in the identification of the parasites<sup>[59]</sup>. Another study utilized a machine learning-based approach to identify unresponsive cases of CL caused by *L. tropica*. Among the various classifier models, the multilayer perceptron classifier showed promising results, achieving an accuracy of 87.8%, a sensitivity of 90.3%, and a specificity of 86%. The study highlighted the potential of AI in disease prognosis and treatment selection, particularly in CL cases<sup>[60]</sup>.

## DISCUSSION

CL manifests as a complex disease, influenced by the intricate interaction among parasite reservoirs, parasites, vectors, climate, ecology, political instability, poverty, and socioeconomic status. The accurate, rapid, and sensitive diagnosis of leishmaniasis heavily relies on the detection of *Leishmania* species. This matter is crucial for the successful implementation of treatment and control strategies<sup>[6]</sup>. Owing to the unavailability of molecular techniques in resource-poor areas, species identification has become unfeasible. As a result, data on the burden of CL are primarily derived from microscopy or clinical descriptions of lesions, such as dry or wet cutaneous lesions<sup>[2]</sup>.

In areas affected by endemic diseases, where the implementation of sophisticated techniques is impractical, a demand arises for a molecular test which is expeditious, while also maintaining a high level of sensitivity and specificity. Moreover, the molecular tests should be designed for laboratory personnel without specialized expertise to ensure their applicability under the demanding conditions<sup>[3]</sup>. The main molecular methods currently employed are outlined in Table 1, highlighting their benefits and drawbacks.

PCR-based assays are widely utilized as the primary method for detecting and typing *Leishmania* species. In this context, kDNA and ITS fragments are frequently utilized in genomic diagnostic protocols, with kDNA being a commonly targeted region for PCR amplification<sup>[10]</sup>. The application of PCR is dependent on having the necessary infrastructure and skilled operators. To address this issue, isothermal diagnostic amplification techniques such as NASBA and LAMP have been developed in recent years as an alternative solution<sup>[3]</sup>. We believe that the use of isothermal diagnostic amplification techniques has the potential to revolutionize the detection of infectious agents in developing countries such as Iran.

## CONCLUSION

Diagnosis of leishmaniasis has gained significant advancements with the introduction of numerous molecular methods. Nevertheless, the practical utilization of these techniques in clinical settings and healthcare facilities still remains limited. Emphasis should be placed on initiatives that improve the usability and cost-effectiveness of molecular diagnostic techniques, as well as the development of AI-based platforms in developing countries.

**Table 1.** An overview of the pros and cons of various molecular diagnostic techniques

Molecular technique	Pros	Cons
Conventional PCR	<ul style="list-style-type: none"> <li>- High level of accuracy and reliability</li> <li>- High specificity and sensitivity</li> <li>- Clear and straightforward diagnostic analyses</li> </ul>	<ul style="list-style-type: none"> <li>- Time consuming</li> <li>- Qualitative approach</li> <li>- Limited detection range</li> </ul>
Nested and semi-nested PCR	<ul style="list-style-type: none"> <li>- Higher sensitivity and specificity in comparison to conventional PCR</li> <li>- An advantageous approach for studying molecular epidemiology within the field</li> </ul>	<ul style="list-style-type: none"> <li>- More time-consuming and expensive than conventional PCR</li> <li>- Qualitative approach</li> </ul>
Multiplex PCR	<ul style="list-style-type: none"> <li>- Simultaneous detection of target genes</li> <li>- Cost effective (lower amounts of dNTPs, enzymes, and other consumables)</li> </ul>	<ul style="list-style-type: none"> <li>- Reduced sensitivity compared to conventional PCR</li> <li>- Accurate design of primers</li> <li>- Extensive optimization tests</li> </ul>
Real-time PCR	<ul style="list-style-type: none"> <li>- Higher levels of specificity and sensitivity compared to conventional PCR</li> <li>- Numerical potential and rapid results</li> <li>- Differentiation of species by analysis of melting temperature</li> </ul>	<ul style="list-style-type: none"> <li>- Complexity in explaining the results</li> <li>- Requires a highly-trained laboratory staff</li> <li>- Requires expensive equipment and reagents</li> </ul>
PCR-ELISA	<ul style="list-style-type: none"> <li>- Higher levels of specificity and sensitivity compared to conventional PCR</li> <li>- Shorter analytical time and lower detection limit</li> </ul>	<ul style="list-style-type: none"> <li>- Lower accuracy in quantification compared to real-time PCR</li> <li>- Requires sophisticated equipment such as an ELISA plate reader</li> <li>- Expensive reagents</li> </ul>
AFLP	<ul style="list-style-type: none"> <li>- Highly reproducible</li> <li>- No sequence data for primer construction are required</li> <li>- High-resolution genotyping of fingerprinting quality</li> </ul>	<ul style="list-style-type: none"> <li>- Requires pure and high molecular weight DNA</li> <li>- Markers usually scored as dominant</li> <li>- Technically demanding</li> </ul>
NASBA	<ul style="list-style-type: none"> <li>- Higher specificity and rapid results</li> <li>- Isothermal nature</li> <li>- Lower detection limits compared to other molecular techniques</li> <li>- Not required expensive equipment</li> </ul>	<ul style="list-style-type: none"> <li>- Susceptible to degradation by RNases</li> <li>- Sensitive to temperature fluctuations</li> </ul>
LAMP	<ul style="list-style-type: none"> <li>- Rapid, simple, and cost-effective</li> <li>- Isothermal nature</li> <li>- Not required expensive equipment</li> </ul>	<ul style="list-style-type: none"> <li>- Sensitive to cross-contamination</li> <li>- False-positive binding and non-specific binding</li> </ul>

## DECLARATIONS

### Acknowledgments

For rectifying grammatical errors and improving writing style, we have used Grammarly (free plugin for browsers).

### Ethical approval

Not applicable.

### Consent to participate

Not applicable.

### Consent for publication

All authors reviewed the results and approved the final version of the manuscript.

### Authors' contributions

SEE: conceptualization, data curation, formal analysis, and supervision; MM: data curation, formal analysis, and writing original draft; HM: writing original draft; MMO: review and editing; AK: review and editing.

### Data availability

All relevant data can be found within the manuscript.

### Competing interests

The authors declare that they have no competing interests.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Supplementary information

The online version does not contain supplementary material.

## REFERENCES

1. Pasquier G, Demar M, Lami P, Zribi A, Marty P, Buffet P, et al. Leishmaniasis epidemiology in endemic areas of metropolitan France and its overseas territories from 1998 to 2020. *PLoS Negl Trop Dis.* 2022; 16(10):e0010745.
2. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. *Lancet Infect Dis.* 2007; 7(9):581-96.
3. de Vries HJ, Schallig HD. Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. *Am J Clin Dermatol.* 2022; 23(6):823-40.
4. Van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. *Clin Microbiol Infect.* 2014; 20(4):286-99.
5. Abadías-Granado I, Diago A, Cerro PA, Palma-Ruiz AM, Gilaberte Y. Cutaneous and mucocutaneous leishmaniasis. *Actas Dermo-Sifiliográficas (Engl Ed).* 2021; doi: 10.1016/j.ad.2021.02.008.
6. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory diagnosis of cutaneous and visceral leishmaniasis: current and future methods. *Microorganisms.* 2020; 8(11):1632.
7. Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. *J Parasit Dis.* 2020; 44(2):253-72.
8. Tsokana CN, Athanasiou LV, Valiakos G, Spyrou V, Manolakou K, Billinis C. Molecular Diagnosis of Leishmaniasis, Species Identification and Phylogenetic Analysis. In: Claborn DM editor. *Leishmaniasis—Trends Epidemiol Diagnosis Treat.* London: In Tech Open; 2014; pp. 161-193.
9. Akhondi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al. *Leishmania* infections: Molecular targets and diagnosis. *Mol Aspects Med.* 2017; 57:1-29.
10. Goto H, Lindoso JAL. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. *Expert Rev Anti Infect Ther.* 2010; 8(4):419-33.
11. Pourmohammadi B, Motazedian MH, Hatam GR, Kalantari M, Habibi P, Sarkari B. Comparison of three methods for diagnosis of cutaneous leishmaniasis. *Iran J Parasitol.* 2010; 5(4):1-8.
12. Shahbazi F, Shahabi S, Kazemi B, Mohebali M, Abadi AR, Zare Z. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. *Parasitol Res.* 2008; 103(5):1159-62.
13. Kermanjani A, Akhlaghi L, Oormazdi H, Hadighi R. Isolation and identification of cutaneous leishmaniasis species by PCR-RFLP in Ilam province, the west of Iran. *J Parasit Dis.* 2017; 41(1):175-9.
14. Teimouri A, Mohebali M, Kazemirad E, Hajjaran H. Molecular identification of agents of human cutaneous leishmaniasis and canine visceral leishmaniasis in different areas of Iran using internal transcribed spacer 1 PCR-RFLP. *J Arthropod Borne Dis.* 2018; 12(2):162-71.
15. Ghatee MA, Mirhendi H, Marashifard M, Kanannejad Z, Taylor WR, Sharifi I. Population structure of *Leishmania tropica* causing anthroponotic cutaneous leishmaniasis in southern Iran by PCR-RFLP of kinetoplastid DNA. *Biomed Res Int.* 2018; 2018:6049198.
16. Darudi S, Mohebali M, Hajjaran H, Fata A, Kazemi-Rad E, Raoofian R. A comparison study between parasitological and molecular methods for diagnosis of acute and chronic anthroponotic cutaneous leishmaniasis. *JoMMID.* 2015; 3(3):52-6.
17. Mesa LE, Manrique R, Muskus C, Robledo SM. Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for cutaneous leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: Systematic review and meta-analysis. *PLoS Negl Trop Dis.* 2020; 14(1):e0007981.
18. Deepachandi B, Weerasinghe S, Soysa P, Karunaweera N, Siriwardana Y. A highly sensitive modified nested PCR to enhance case detection in leishmaniasis. *BMC Infect Dis.* 2019; 19(1):623.
19. Feiz Haddad MH, Ghasemi E, Maraghi S, Tavala M. Identification of *Leishmania* species isolated from human cutaneous leishmaniasis in Mehran, Western Iran using nested PCR. *Iran J Parasitol.* 2016; 11(1):65-72.
20. Shirian S, Oryan A, Hatam GR, Panahi S, Daneshbod Y. Comparison of conventional, molecular, and immunohistochemical methods in diagnosis of typical and atypical cutaneous leishmaniasis. *Arch Pathol Lab Med.* 2014; 138(2):235-40.
21. Khosravi A, Sharifi I, Dortaj E, Afshar AA, Mostafavi M. The present status of cutaneous leishmaniasis in a recently emerged focus in south-west of Kerman Province, Iran. *Iran J Public Health.* 2013; 42(2):182-7.
22. Ghasemian M, Maraghi S, Samarbafzadeh AR, Jelowdar A, Kalantari M. The PCR-based detection and identification of the parasites causing human cutaneous leishmaniasis in the Iranian city of Ahvaz. *Ann Trop Med Parasitol.* 2011; 105(3):209-215.
23. Maraghi S, Mardanshah O, Rafiei A, Samarbafzadeh A, Vazirianzadeh B. Identification of cutaneous leishmaniasis agents in four geographical regions of Khuzestan province using Nested PCR. *Jundishapur J Microbiol.* 2013; 6(4):e4866.
24. Parvizi P, Mauricio I, Aransay AM, Miles MA, Ready PD. First detection of *Leishmania major* in peridomestic *Phlebotomus papatasi* from Isfahan province, Iran: comparison of nested PCR of nuclear ITS ribosomal DNA and semi-nested PCR of minicircle kinetoplast DNA. *Acta Trop.* 2005; 93(1):75-83.
25. Oshaghi MA, Yaghobi-Ershadi MR, Abbassi M, Parvizi

P, Akhavan AA, Foroshani AR, et al. Detection of *Leishmania major* in naturally infected sand flies using semi nested-PCR. *Iran J Public Health*. 2008; 37(4):59-64.

26. El-Beshbisy HA, Al-Ali KH, El-Badry AA. Molecular characterization of *Leishmania* infection in sand flies from Al-madinah Al-munawarah province, western Saudi Arabia. *Exp Parasitol*. 2013; 134(2):211-5.

27. Arefkhah N, Shafiei S, Saadat Nia A, Moshfe A. Identification of cutaneous leishmaniasis-causing species using semi-nested PCR in Kohgiluyeh and Boyer-Ahmad province during 2013-2019. *Armaghanj*, 2022; 27(4):497-506.

28. Karimian Shirazi M, Razmi G, Naghibi A. Molecular Identification of *Leishmania* species causing cutaneous Leishmaniasis In Mashhad area, Iran. *JBUMS*. 2014; 21(2):237-45.

29. Badirzadeh A, Mohebali M, Ghasemian M, Amini H, Zarei Z, Akhouni B, et al. Cutaneous and post kala-azar dermal leishmaniasis caused by *Leishmania infantum* in endemic areas of visceral leishmaniasis, northwestern Iran 2002–2011: a case series. *Pathog Glob Health*. 2013; 107(4):194-7.

30. de Cássia-Pires R, de Melo MD, Barbosa RD, Roque AL. Multiplex PCR as a tool for the diagnosis of *Leishmania* spp. kDNA and the *gapdh* housekeeping gene of mammal hosts. *PLoS One*. 2017; 12(3):e0173922.

31. Conter CC, Lonardoni MV, Aristides SM, Cardoso RF, Silveira TG. New primers for the detection *Leishmania* species by multiplex polymerase chain reaction. *Parasitol Res*. 2018; 117:501-1.

32. Gonçalves-de-Albuquerque SDC, Silva RP, Moraes RCSD, Trajano-Silva LA, Régis-da-Silva CG, Brandão Filho SP, et al. Tracking false-negative results in molecular diagnosis: proposal of a triplex-PCR based method for leishmaniasis diagnosis. *J Venom Anim Toxins Incl Trop Dis*. 2014; 20: article number 16.

33. Harris E, Kropf G, Belli A, Rodriguez B, Agabian N. Single-step multiplex PCR assay for characterization of New World *Leishmania* complexes. *J Clin Microbiol*. 1998; 36(7):1989-95.

34. Nateghi Rostami M, Darzi F, Farahmand M, Aghaei M, Parvizi P. Performance of a universal PCR assay to identify different *Leishmania* species causative of Old World cutaneous leishmaniasis. *Parasit Vectors*. 2020; 13:article number 431.

35. Safari Z, Saadati M, Nazarian S, Heiat M, Mirzaei M. Diagnosis of cutaneous leishmaniasis by multiplex PCR. *JSSU*. 2010; 18(2):118-26.

36. Adams G. A beginner's guide to RT-PCR, qPCR and RT-qPCR. *Biochem (Lond)*. 2020; 42(3):48-53.

37. Khademvatan S, Neisi N, Maraghi S, Saki J. Diagnosis and identification of *Leishmania* spp. from Giemsa-stained slides, by real-time PCR and melting curve analysis in south-west of Iran. *Ann Trop Med Parasitol*. 2011; 105(8):559-65.

38. Khosravi S, Hejazi SH, Hashemzadeh M, Eslami G, Darani HY. Molecular diagnosis of old world leishmaniasis: Real-time PCR based on tryparedoxin peroxidase gene for the detection and identification of: *Leishmania*: spp. *J Vector Borne Dis*. 2012; 49(1):15-18.

39. Fekri-SoofiAbadi M, Fekri M, Moradabadi A, Vahidi R, Shamsi-Meymandi S, Dabiri D, et al. Ability of real-time PCR for differential diagnosis of various forms of cutaneous leishmaniasis: a comparative study with histopathology. *BMC Res Notes*. 2019; 12:615.

40. Fotouhi-Ardakani R, Ghafari SM, Ready PD, Parvizi P. Developing, modifying, and validating a TaqMan real-time PCR technique for accurate identification of *Leishmania* parasites causing most leishmaniasis in Iran. *Front Cell Infect Microbiol*. 2021; 11:731595.

41. Merino-Espinosa G, Rodríguez-Granger J, Morillas-Márquez F, Tercedor J, Corpas-López V, Chiheb S, et al. Comparison of PCR-based methods for the diagnosis of cutaneous leishmaniasis in two different epidemiological scenarios: Spain and Morocco. *J Eur Acad Dermatol Venereol*. 2018; 32(11):1999-2003.

42. Samimi A, Jorjani ON, Sharifi Z, Koohsar F, Kalavi K, Mesgarian F, et al. Detection of *Leishmania major* using PCR-ELISA. *Mljgoums*. 2022; 16(3):24-9.

43. Kobets T, Badalová J, Grekov I, Havelková H, Svbodová M, Lipoldová M. Leishmania parasite detection and quantification using PCR-ELISA. *Nat Protoc*. 2010; 5(6):1074-80.

44. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M. Detection of *Leishmania infantum* kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. *Am J Trop Med Hyg*. 2008; 79(6):839-42.

45. Restrepo CM, Llanes A, Lleonart R. Use of AFLP for the study of eukaryotic pathogens affecting humans. *Infect Genet Evol*. 2018; 63:360-9.

46. Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing *Leishmania* species of visceral and cutaneous forms. *Acta Trop*. 2010; 113(2):202-6.

47. Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Saffari M, Raoofian R, Hajjaran H, et al. Identification of antimony resistance markers in *Leishmania tropica* field isolates through a cDNA-AFLP approach. *Exp Parasitol*. 2013; 135(2):344-9.

48. Khadem Erfan MB, Mohebali M, Kazemi-Rad E, Hajjaran H, Edrissian G, Mamishi S, et al. Downregulation of calcineurin gene is associated with Glucantime® resistance in *Leishmania infantum*. *Iran J Parasitol*. 2013; 8(3):359-66.

49. van der Meide WF, Schoone GJ, Faber WR, Zeegelaar JE, de Vries HJ, Ozbel Y, et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of *Leishmania* parasites in skin biopsy samples. *J Clin Microbiol*. 2005; 43(11):5560-6.

50. van der Meide WF, Peekel I, van Thiel PP, Schallig HD, De Vries HJ, Zeegelaar JE, et al. Treatment assessment by monitoring parasite load in skin biopsies from patients with cutaneous leishmaniasis, using quantitative nucleic

acid sequence-based amplification. *Clin Exp Dermatol.* 2008; 33(4):394-9.

51. Niazi A, Koohsar F, Ghaffarifar F, Ziaeи-Hezarjaribi H, Mesgarian F, Jorjani O. Sensitivity and specificity of nucleic acid sequence-based amplification method for diagnosis of cutaneous *Leishmaniasis*. *Milgoums* 2014; 8(2):20-6.

52. Shirbazou SH, Dalimiasl A, Forouzandeh MM, Ghaffarifar F. Standardization of NASBA method by using 18s rRNA gene for identification of *Leishmania major* parasite (In Persian). *Kowsar Med J.* 2009; 14(3):137-42.

53. Niazi A, Jorjani ON, Nikbakht H, Gill P. A nanodiagnostic colorimetric assay for 18S rRNA of *Leishmania* pathogens using nucleic acid sequence-based amplification and gold nanorods. *Mol Diagn Ther.* 2013; 17:363-70.

54. Avendaño C, Patarroyo MA. Loop-mediated isothermal amplification as point-of-care diagnosis for neglected parasitic infections. *Int J Mol Sci.* 2020; 21(21):7981.

55. Adams ER, Schoone G, Versteeg I, Gomez MA, Diro E, Mori Y, et al. Development and evaluation of a novel loop-mediated isothermal amplification assay for diagnosis of cutaneous and visceral leishmaniasis. *J Clin Microbiol.* 2018; 56(7):e00386-18.

56. Saki J, Amraee D, Ghasemian M. Comparison of nested-PCR and loop-mediated isothermal amplification for cutaneous leishmaniasis diagnosis. *Jundishapur J Microbiol.* 2019; 12(8): Available from: <https://sid.ir/paper/317806/en>.

57. Salari S, Taghdiri A, Bamorovat M, Sharifi I, Almani PG. A novel rapid LAMP test for identification of cutaneous leishmaniasis: an evaluation and comparative analysis of three molecular methods. *Microb Pathog.* 2022; 169:105612.

58. Taslimi Y, Habibzadeh S, Goyonlo VM, Akbarzadeh A, Azarpour Z, Gharibzadeh S, et al. Tape-disc-loop-mediated isothermal amplification (TD-LAMP) method as noninvasive approach for diagnosis of cutaneous leishmaniasis caused by *L. tropica*. *Heliyon.* 2023; 9(11):e21397.

59. Zare M, Akbarialiabad H, Parsaei H, Asgari Q, Alinejad A, Bahreini MS, et al. A machine learning-based system for detecting leishmaniasis in microscopic images. *BMC Infect Dis* 2022; 22(1):48.

60. Bamorovat M, Sharifi I, Rashedi E, Shafian A, Sharifi F, Khosravi A, et al. A novel diagnostic and prognostic approach for unresponsive patients with anthropomorphic cutaneous leishmaniasis using artificial neural networks. *PLoS One* 2021; 16(5):e0250904.